Celtic Biotech Ltd

Celtic Biotech Ltd is a pioneering force in biotechnology research, dedicated to developing innovative therapies for the treatment of solid cancers and pain management. With a focus on enhancing survival rates, improving quality of life, and reducing treatment costs, Celtic Biotech Ltd is committed to making a significant impact on healthcare. The company's research is primarily centered on solid tumors, with non-small-cell lung cancer (NSCLC) as a key initial target.

Celtic Biotech Ltd’s lead candidate, CB-24 (Crotoxin), derived from specialized receptor binding proteins found in snake venom, has demonstrated high toxicity to various tumor cell lines in pre-clinical and early clinical studies. This groundbreaking research holds the potential to revolutionize cancer treatment and provide new hope for patients worldwide. Operating from its primary location in Dublin, IE, Celtic Biotech Ltd is strategically positioned to advance its research and development efforts.

Celtic Biotech Ltd continues to push the boundaries of medical science, striving to deliver effective and natural solutions for cancer and pain management. The company’s commitment to innovation and patient well-being drives its ongoing research and development initiatives. We invite the manager of Celtic Biotech Ltd to create a customized and exclusive company showcase and product listing on our platform, to further highlight their groundbreaking work and attract new opportunities.